Kornimate/medical-research-clean huggingface dataset:
health outcomes of parents with cystic fibrosis-aim 2

Conditions: Cystic Fibrosis; Parenthood Status

Summary: the goal of this observational prospective study is to determine the health impact of parenthood on united states (us) people with cf in the era of cf transmembrane regulator protein (cftr) modulators. the investigators will collect physical and mental health data to comprehensively evaluate the impact of parenthood in cf with widespread highly effective cftr modulator use. the main hypotheses this study aims to examine are: h1: parents with cf and moderate-to-severe depression have more rapid change in ppfev1 (percent predicted forced expiratory volume in one second) versus those with mild or no depression. h2: parents with cf who have more parental responsibility and/or stress have more rapid ppfev1 (percent predicted forced expiratory volume in one second) change than those with less responsibility/stress h3: parents using cftr modulators have decreased ppfev1 (percent predicted forced expiratory volume in one second) change versus those not using cftr modulators participants will complete quarterly surveys during the first year of parenthood and biannual surveys, thereafter, using the computer-based survey system on an ipad protected for infection control or via personal device or computer via emailed survey link.

the investigators will follow 146 new parents of children \<5 years of age at 18 participating us adult cf centers to assess the primary outcome of percent predicted forced expiratory volume in one second (ppfev1) up to 5 years after becoming a parent. a prospective approach will capture the immediate and long-term impact of the use of the highly effective cftr modulator eti (elexacaftor/tezacaftor/ivacaftor) by \~90 percent of us adults with cf. by combining objective health measures and participant surveys, the investigators can comprehensively assess the psychosocial impacts of parenthood and explore the interplay between the parenting role and physical and mental health. the investigators anticipate identifying modifiable factors that may ameliorate negative health impacts of parenthood. the investigators will conduct hypothesis-generating, semi-structured dyadic interviews with a subset of parents and their key supports (partner/family/friend) to inform future interventions. the investigators have selected qualitative methodology to avoid preconceived theories/hypotheses.

Eligibility criteria:
inclusion criteria: * diagnosed with cystic fibrosis via sweat test or genotype analysis * became a first-time parent (including foster parent, step parent, adoptive parent, or legal guardian) to a child under 5 years of age within the last 90 days exclusion criteria: * undergone a lung transplant * does not speak/read english or spanish

Keywords: cystic fibrosis parenthood highly effective modulator therapy
biomarkers as predictors of chronic heart failure in patients with type 2 diabetes

Conditions: Type 2 Diabetes; Chronic Heart Failure

Summary: a cohort study on patients with type 2 diabetes to investigate possible biomarkers as predictors of chronic heart failure.

a cohort study on 500 patients with type 2 diabetes without known heart disease and age \> 50 years of age. on inclusion and on yearly basis, patients are evaluated by echocardiography, ecg, blood tests to examine nt-probnp, hs-crp, troponin, kidney function and 6 minutes hall walk test.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * age \> 50 years exclusion criteria: * history of acute or chronic heart failure * history of ischemic heart disease
facial hair reduction using intense pulsed light (ipl) & alexandrite laser

Conditions: Hirsutism

Summary: the purpose of this study is to compare the efficacy of the ipl system 650advance handpiece with the alexandrite laser for the purposes of female facial hair reduction

this is a randomised (splitface)controlled trial, comparing the use of the intense pulsed light (ipl) system 650 advance handpiece against the alexandrite laser for the purposes of female facial hair reduction. previous studies have shown that the alexandrite laser is superior to ipl in achieving hair reduction. a new handpiece (lynton, lumina 650 advance) available for the ipl system is designed to further optimise its use in removing female facial hair (particularly those hair colours previously unresponsive to treatment). this study will compare the alexandrite laser to the ipl system using the new handpiece. this may lead to improvements in the treatment of female patients with male pattern facial hair. female patients referred to our facial hair reduction service will be recruited to this study. 1/2 their face will be treated with ipl and 1/2 with alexandrite laser. each participant will receive 6 full treatments at approximately 6 weekly intervals. participants will be asked to fill in a satisfaction questionnaire and have clinical photographs taken pre treatment and at 1 and 3months post final treatment. all treatments will be carried out in our dedicated laser suite at glasgow royal infirmary.

Eligibility criteria:
inclusion criteria: * female patients * minimum age 16years old * fitzpatrick skin types i-iii * significant facial hair. exclusion criteria: * fitzpatrick skin types iv-vi * age less than 16years old * males * no visible facial hair growth * use of electrolysis or depilatory creams 6weeks prior to treatment * active acnes * current coldsore * previous facial hair removal with laser or ipl in past 12 months * sun tanned skin

Keywords: hirsutism laser hair reduction ipl intense pulsed light
investigation of glp1-receptor agonists in men with prostate cancer taking androgen deprivation therapy

Conditions: Prostate Cancer

Summary: gain pc control is a study investigating glucagon-like peptide-1 receptor agonists in men with prostate cancer who are being treated with androgen deprivation therapy.

gain pc control is an open-label single-arm phase iv trial that will evaluate 1) the safety and tolerability of glucagon-like peptide-1 receptor agonists (glp-1 ras) in men with prostate cancer (pc) treated with androgen deprivation therapy (adt); 2) the effects of glp-1 ras on weight, waist circumference, blood pressure, hba1c, lipids, psa and creatinine, estimated glomerular filtration rate in men with pc treated with adt. patients who meet eligibility criteria and who provide informed consent will be enrolled to receive semaglutide. following enrollment, all participants will undergo a baseline visit, a 1-month telephone follow-up visit, 3-month visit and 6-month (close-out) visit. the semaglutide dose will be 0.25mg subcutaneously once weekly for weeks 1-4, then 0.5mg once weekly for weeks 5-8, then 1mg once weekly for weeks 9-12, then 1.7mg once weekly for weeks 13-16, and then 2.4mg for the remainder of the trial. semaglutide dose may be decreased in the case of adverse events to the highest tolerated dose.

Eligibility criteria:
inclusion criteria: * have a physician diagnosis of pc * must be receiving or planned to receive adt (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor) * elevated bmi 1. ≥30kg/m2 or 2. ≥27kg/m2 in the presence of at least one of hypertension, type 2 diabetes, obstructive sleep apnea or dyslipidemia exclusion criteria: * type 1 diabetes * taking a glp-1 ra * \<18 years of age * history of pancreatitis * personal or family history of medullary cancer of the thyroid * multiple endocrine neoplasia type 2

Keywords: androgen deprivation therapy glp-1 receptor agonists
the size of pelvic hematoma can be a predictive factor for angioembolization

Conditions: Multiple Pelvic Fractures

Summary: unstable pelvic fracture with bleeding can be fatal, with a mortality rate of up to 40%. therefore, early detection and treatment are important in unstable pelvic trauma. we investigated the early predictive factors for possible embolization in patients with hemodynamically unstable pelvic trauma. the purpose of this study was to predict the necessity of embolization and the timing of angiography using ct scans.

background: unstable pelvic fracture with bleeding can be fatal, with a mortality rate of up to 40%. therefore, early detection and treatment are important in unstable pelvic trauma. we investigated the early predictive factors for possible embolization in patients with hemodynamically unstable pelvic trauma. methods: from january 2011 to december 2013, 46 patients with shock arrived at a single hospital within 24 h after injury. of them, 44 patients underwent computed tomography (ct) after initial resuscitation, except for 2 who were dead on arrival. nine patients with other organ injuries were excluded. seventeen patients underwent embolization. a single radiologist measured the width (longest length in axial view) and length (longest length in coronal view) of pelvic hematoma on ct scans. demographic, clinical, and radiological data were reviewed retrospectively.

Eligibility criteria:
inclusion criteria: * patients with shock (systolic blood pressure \<90 mmhg) arrived at a single hospital within 24 h after injury after pelvic fracture exclusion criteria: * declared dead on arrival * patients with other organ injuries

Keywords: angioembolization computed tomography
spinal cord injury series of tampere - retrospective study

Conditions: Spinal Cord Injury

Summary: this prospective study will assess thoroughly functional deficits and their significance in the light of rehabilitation in spinal cord injured patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of spinal cord injury

Keywords: spinal cord injury(sci) diffusion tensor imaging(dti) tractography
extracorporeal shock wave therapy (eswt) for the treatment of spasticity in persons with spinal cord injury

Conditions: Spinal Cord Injury; Spasticity

Summary: spasticity is the most problematic self-reported secondary medical problem in patients with spinal cord injury. it has the potential to negatively influence quality of life through restricting activities of daily living. problematic spasticity can cause pain and fatigue, disturb sleep, contribute to the developement of contractures and pressure ulcers, and has a negative effect on patients morbidity. for this reason there is enormous interest in therapeutic interventions addressing to decrease spasticity in persons with spinal cord injury. recently, studies reported positive effects of extracorporeal shock wave therapy on spasticity in patients with stroke, focal limb dystonia and cerebral palsy. to date, no studies are published, assessing the effect of extracorporeal shock wave therapy on focal spasticity in patients with spinal cord injury. the purpose of this study is to investigate the effect of a one-time eswt on lower limb spasticity in patients with an incomplete spinal cord injury.


Eligibility criteria:
inclusion criteria: * traumatic or non traumatic spinal cord injury * minimum age: 18 years * minimum time since spinal cord injury: two years * lesion: c3-th10 * american association of spinal cord injury impairment score c and d * focal spasticity in the adductor muscles and/ or triceps surae * ability to walk 14 meters * spasticity/clonus/spasms disturbing the activities of daily living or participation exclusion criteria: * changes in spasticity medication during the last 3 months * treatment with botulinum toxin during the last 6 months * anticoagulant medication * thrombosis * malignant tumors * pregnancy * inflammations or skin lesions in the treated area * acute urinary tract infection * intended change in spasticity medication within 5 days after intervention

Keywords: extracorporal shock wave therapy (eswt) spasticity spinal cord injury
effect of preoperative oral carbohydrates on the glycemic variability of diabetic patients

Conditions: Diabetes

Summary: preoperative carbohydrate drink intake attenuate insulin resistance. however, carbohydrate loading may compromise blood glucose control in patients with diabetes. there is some evidence that oral carbohydrate loading may be safe in patients with type 2 diabetes. therefore, the investigators aim to evaluate whether preoperative carbohydrate intake affects insulin resistance and glycemic variability in patients with diabetes. fifty patients scheduled for total knee arthroplasty will be divided into carbohydrate (n=25) and control (n=25) groups. randomly selected patients of the carbohydrate group are given 400ml of 12.8 g/100 ml carbohydrate beverage 2-3 hours before their scheduled operation. in contrast, patients in the control group are fasted from water 2 hours before surgery according to standard protocol.


Eligibility criteria:
inclusion criteria: * 1. patients undergoing total knee arthroplasty exclusion criteria: * 1. patients with contraindications to spinal anesthesia (local infection, clotting disorders, anatomical abnormalities, sepsis, etc.) * 2. patients with gastroesophageal reflux disease, gastric emptying disorders, inflammatory bowel disease, or previous treatment for intra-abdominal cancer * 3. patients with chronic renal disease or severe cardiovascular disease * 4. hba1c \>69 mmol/mol or bmi \>30 kg/m2 * 5. a duration of ≥5 hours between consumption of cho and initiation of surgery. * 6. the subject is a foreigner or illiterate
comparison of microneedling vs. autologous concentrated growth factor for the treatment of female androgenetic alopecia

Conditions: Androgenetic Alopecia

Summary: microneedling and autologous concentrated growth factor (cgf) have established their potential effect in inducing hair regrowth. no study has compared the effect of microneedling and cgf in the treatment of female androgenetic alopecia (aga).

microneedling is a minimally invasive technique consisting of sterile microneedles for repetitive cutaneous puncturing that increase hair regrowth by growth factor release. concentrated growth factor (cgf) is a form of platelet concentrate (pc) and concentrates higher levels of growth factors because of its varying programmed centrifugation process. previous studies have showed that cgf injection in hairless scalp could enhance the hair density and optimize the hairless appearance in aga patients. both microneedling and cgf have established their potential effect in inducing hair regrowth. no study has compared the effect of microneedling and cgf in the treatment of female androgenetic alopecia.

Eligibility criteria:
inclusion criteria: 1. age between 18 and 65 years;； 2. clinical diagnosis of female pattern hair loss； 3. no previous laser treatments for aga in the past six months before enrollment； 4) willingness to provide pictures and follow-up studies. exclusion criteria: 1. if presented with severe diseases of internal organs, eyes, or skin; 2. inflammation, infection, or unhealed wounds on the skin around the site of treatment on the head; 3. systematic treatment with corticosteroids or other immunosuppressants and immunomodulators in the past 3 months.
clinical decision biological biomarker and prognosis prediction of hepatocellular carcinoma by deep learning

Conditions: Hepatocellular Carcinoma; Contrast-enhanced Ultrasound; Prognosis; Surgery; Ablation

Summary: developing a deep learning model based on contrast-enhanced ultrasound (ceus) to predict the prognosis of hepatocellular carcinoma (hcc) and aid choose operation decisions

collecting ceus and clinical data of hcc from different institutions retrospectively. developing a deep learning model based on ceus to predict the prognosis of hcc. developing a deep learning model based on ceus to choose a better operation (ablation or surgery) of hcc patients. then, validating the deep learning model in the prospective data.

Eligibility criteria:
inclusion criteria: * patients with hcc (ia, ib, iia stage) china liver cancer staging who underwent resection or ablation * without macro-vascular invasion * child-pugh a/b grade * hcc is proved by pathological examination or two enhanced imaging * ceus (sonovue or sonozoid) images are performed two weeks before the operation * invasive biomarker or prognosis of hcc available * ceus images are included in at least three stages (arterial phase, portal phase, and late phase) exclusion criteria: * postop follow-up loss or expired less than 3 months * patients with co-malignancy * poor images quality for analyzing
serum lactate and ulcerative colitis

Conditions: Ulcerative Colitis

Summary: patients presenting with severe symptoms of ulcerative colitis (uc) require hospital admission for urgent assessment and therapy. endoscopic examination of the rectum and/or distal colon is often performed to assess severity and obtain tissue for histopathologic evaluation, but this is often extended to full colonoscopy to assess the extent of bowel involvement. full colonoscopy is hazardous in this setting

biomarkers like erythrocyte sedimentation rate (esr) and c reactive protein (crp) are used for monitoring the disease activity but present a low specificity and sensitivity in uc . there are fecal biomarkers with better performance for detecting disease activity in uc like fecal calprotectin and lactoferrin, however, are very expensive platelets present granules with interleukin 8 (il-8) which is a potent neutrophil chemoattractant and its cytoplasm contains p-selectin that induces overproduction of superoxide and the formation of neutrophil-platelet aggregates, which are elevated in patients with uc. the inhibition of this aggregates suppress the appearance of colon inflammation the mean platelet volume (mpv) is correlated to the uc activity as also the increase of white blood count (wbc) mainly neutrophils. the interaction of neutrophil-platelet is a possible explanation of the high prevalence of thrombosis in uc due to the formation of neutrophil extracellular traps (nets) through toll-like receptor 4 (tlr-4)

Eligibility criteria:
inclusion criteria: any patient who is above age of 18 years old and diagnosed to have uc based on combination between clinical, laboratory, radiological, endoscopic and/or histopathological data whatever the course of the disease exclusion criteria * patients with inflammatory bowel disease (ibd) other than uc as those with crohn's disease or microscopic colitis * pregnant patients with ulcerative colitis. * patients with uc who are under age of 18 years old * patient's refusal
long-term prospective registry in prostate cancer patients from diverse urology practice settings following prolaris® testing

Conditions: Prostate Cancer

Summary: this registry will evaluate treatment selection for patients with newly diagnosed, localized prostate cancer following prolaris testing. it will measure the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment, and clinical outcomes.

to evaluate use of the prolaris score in treatment management decisions in an ethnically and racially diverse population of men who have been newly diagnosed with prostate cancer and who are potential candidates for active surveillance. this registry will evaluate oncologic and co-morbidity outcomes in patients who receive prolaris testing. additionally, the registry will measure the prevalence and distribution of pathogenic mutations in hereditary cancer risk-associated genes among men with prostate cancer who meet national cancer center network (nccn) criteria for hereditary cancer genetic testing. the primary objective of this registry is to evaluate initial selection of active surveillance (active surveillance selection) versus definitive therapy (dt) among men with newly diagnosed prostate cancer who make treatment decisions with prolaris testing, and among patient subsets defined by race/ethnicity. the secondary objectives of the registry are to evaluate progression of from active surveillance to definitive therapy over time and prostate cancer-associated morbidities that affect quality of life among men with newly diagnosed prostate cancer and who undergo prolaris testing, and among patient subsets defined by racial/ethnic background and ancestry.

Eligibility criteria:
inclusion criteria: * age 18 years or older on date of enrollment. * diagnosed within the past six months with histologically proven, localized adenocarcinoma of prostate determined via transrectal ultrasonography and biopsy of at least 10 prostate sites. * received prolaris testing and a resulting ccr score from the diagnostic biopsy sample as standard of care. * can be monitored for disease progression according to standard of care (e.g., current nccn guidelines). exclusion criteria: * estimated life expectancy \< 10 years. * clinical evidence of metastasis or lymph node involvement. * received pelvic radiation prior to biopsy. * received androgen deprivation therapy (adt) prior to biopsy; however, 5 alpha- reductase inhibitor (5-ari) use is permitted. * plan to use prca-specific prognostic testing other than psa for treatment decision making during active surveillance. * currently participating in an interventional clinical trial. * unable to provide routine clinical informed consent.

Keywords: prostate cancer active surveillance active surveillance durability prostate cancer treatment selection prostate cancer risk stratification prostate cancer oncological outcomes
pilot study of rna as a biomarker for autosomal dominant polycystic kidney disease

Conditions: Chronic Kidney Disease; Polycystic Kidney, Autosomal Dominant

Summary: the aim of this pilot project is to assess the potential of urine micro-rnas (mirna) as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (adpkd) compared with patients with other causes of chronic kidney disease.

proteins and small molecules in urine (biomarkers) have been used to probe for kidney and systemic diseases for hundreds of years. urine reportedly contains a type of molecule called microrna (mirnas) that regulate a large number of biological processes. impaired function of mirnas is now recognized in an increasing number of disease processes. in the search for new biomarkers, the regulatory function of mirnas and the relative simplicity and precision of characterizing mirnas, are potential advantages when compared to traditional biomarkers. the aim of this pilot project is to assess the potential of urine mirnas as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (adpkd), the most prevalent inherited cause of kidney failure. individuals with other causes of chronic kidney disease (e.g., diabetes, glomerulonephritis), who are matched for key characteristics (e.g. age, sex, level of kidney function) will serve as the control population. a technique for isolation of mirnas from urine samples will be tailored for the specific needs of this project. biochemical and computational analysis of small rnas from these samples will provide urine mirna profiles and key variability statistics that will be use to design follow-up projects involving patients with kidney disease.

Eligibility criteria:
inclusion criteria: 1. male or female subject, 18 years of age or older, with diagnosis of adpkd or non-pkd-ckd 2. if female, not pregnant. 3. willing and able to understand and sign informed consent exclusion criteria: 1. presenting with any signs or symptoms of an infectious disease 2. bacterial infection determined by urine culture 3. use of systemic steroids within a week prior to screening 4. history, physical, or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the principal investigator, make the candidate ineligible for the study.

Keywords: chronic kidney disease (ckd) autosomal dominant polycystic kidney disease (adpkd)